# Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

> **NCT06357676** · PHASE1,PHASE2 · RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 27 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography
- **PROCEDURE:** FDG-Positron Emission Tomography
- **BIOLOGICAL:** Glofitamab
- **DRUG:** Ibrutinib
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Obinutuzumab

## Key facts

- **NCT ID:** NCT06357676
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-29
- **Primary completion:** 2027-11-01
- **Final completion:** 2029-11-01
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-01-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06357676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06357676, "Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06357676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*